Achillion Pharmaceuticals (ACHN) Given “Buy” Rating at Leerink Swann
Leerink Swann restated their buy rating on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) in a report issued on Monday. The firm currently has a $5.00 price target on the biopharmaceutical company’s stock. Leerink Swann also issued estimates for Achillion Pharmaceuticals’ Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at ($0.17) EPS, Q3 2018 earnings at ($0.17) EPS and Q4 2018 earnings at ($0.18) EPS.
Several other research analysts have also commented on ACHN. BidaskClub upgraded shares of Achillion Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, August 16th. ValuEngine lowered shares of Achillion Pharmaceuticals from a sell rating to a strong sell rating in a research note on Monday, September 11th. Robert W. Baird restated a neutral rating and set a $4.00 price target (down previously from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Ladenburg Thalmann Financial Services dropped their price target on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a buy rating on the stock in a research note on Tuesday, September 12th. Finally, Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, September 14th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $5.13.
Achillion Pharmaceuticals (NASDAQ ACHN) opened at $2.86 on Monday. Achillion Pharmaceuticals has a 12 month low of $2.85 and a 12 month high of $5.66.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same quarter last year, the business posted ($0.15) EPS. sell-side analysts anticipate that Achillion Pharmaceuticals will post -0.63 earnings per share for the current year.
In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $2.75, for a total value of $50,510,201.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 7.24% of the company’s stock.
Large investors have recently bought and sold shares of the stock. RTW Investments LP boosted its holdings in Achillion Pharmaceuticals by 392.9% in the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock valued at $35,201,000 after purchasing an additional 6,249,312 shares during the period. Janus Henderson Group PLC bought a new stake in Achillion Pharmaceuticals in the 2nd quarter valued at $20,778,000. Sarissa Capital Management LP bought a new stake in Achillion Pharmaceuticals in the 3rd quarter valued at $9,594,000. Dimensional Fund Advisors LP boosted its holdings in Achillion Pharmaceuticals by 75.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after purchasing an additional 1,407,108 shares during the period. Finally, Senzar Asset Management LLC bought a new stake in Achillion Pharmaceuticals in the 2nd quarter valued at $4,966,000. Institutional investors and hedge funds own 76.93% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Achillion Pharmaceuticals (ACHN) Given “Buy” Rating at Leerink Swann” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/achillion-pharmaceuticals-achn-given-buy-rating-at-leerink-swann/1759093.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.